We investigated whether the effects of intestinal glucuronidation on the first-pass effect can be predicted from in vitro data for UDP-glucuronosyltransferase (UGT) substrates. Human in vitro intrinsic glucuronidation clearance (CL int, UGT ) for 11 UGT substrates was evaluated using pooled intestinal microsomes (4.00-4620 l ⅐ min ؊1 ⅐ mg
Introduction
Because many drugs are metabolized by UDP-glucuronosyltransferases (UGTs) (Williams et al., 2004) , the related conjugation reaction glucuronidation may contribute to the pharmacokinetics of these drugs. Although hepatic glucuronidation has received more interest, attention to intestinal glucuronidation has been growing (Cubitt et al., 2009; Mizuma, 2009) . A good example is raloxifene, which is used in the prevention of osteoporosis in postmenopausal woman. This drug is a substrate for UGT1A8 and UGT1A10, and glucuronidation is associated with low human bioavailability (Mizuma, 2009) , which is expressed as the product of oral absorbability (F a ), intestinal availability (F g ), and hepatic availability (F h ). UGT1A8 and UGT1A10 are unlike most of the other 17 known UGT isoforms because they are expressed in the human intestine, not liver (Ohno and Nakajin, 2009) . Despite evidence that intestinal glucuronidation may affect drug pharmacokinetics in humans, there are only limited tools for predicting the human F a F g of drugs metabolized by intestinal UGTs.
One method is the simplified intestinal availability (SIA) model (Kadono et al., 2010) , which predicts human F a F g from in vitro data for highly permeable CYP3A4 substrates as shown in eq. 1:
where CL met, P450 represents the in vitro intrinsic intestinal clearance (CL int, P450 ) normalized by the CL int, P450 of midazolam and ␣ represents an empirical scaling factor, which is obtained from the relationship between F a F g and CL met, P450 for drugs with human F a F g data. The SIA model can even be used to predict the F a F g of drugs that are highly permeable P-glycoprotein (P-gp) substrates. P-gp is an efflux transporter in human intestine and has the potential to reduce drug absorption. More importantly for this study, the SIA model has also been reported to predict the F a F g of UGT substrates in rats (Furukawa et al., 2012) . However, its ability to predict human F a F g values of UGT substrates remains unclear. Therefore, the aims of this study were to investigate the relationship between in vitro human intestinal glucuronidation clearance and F a F g in humans and to clarify whether intestinal availability of UGT substrates can be predicted using the SIA model.
Materials and Methods
Materials. Raloxifene, tolcapone, and entacapone were purchased from Toronto Research Chemicals Inc. (North York, ON, Canada) . Quercetin, diclofenac, tolfenamic acid, gemfibrozil, indomethacin, and UDP-GlcUA were purchased from Sigma-Aldrich (St. Louis, MO). Telmisartan and etodolac were purchased from LKT Laboratories (St. Paul, MN). Bazedoxifene was purchased from Chemtos, LLC Laboratories (Austin, TX). Pooled human intestinal microsomes (HIM; n ϭ 10) were purchased from XenoTech, LLC (Lenexa, KS). Recombinant UGT Supersomes (UGT1A1, UGT1A3, UGT1A4, UGT1A6 -UGT1A10, UGT2B4, UGT2B7, UGT2B15, and UGT2B17) expressed in baculovirus-infected insect cells were purchased from BD Gentest (Woburn, MA). All other chemicals and reagents were of an analytical grade and readily available from commercial sources.
In Vitro Glucuronidation. In vitro glucuronidation was measured using a procedure published previously (Nakamori et al., 2011) . Except for quercetin and telmisartan, each substrate was dissolved in 50% acetonitrile to 50 M. Quercetin was dissolved to 500 M because of the detection range limit. Telmisartan was dissolved in 50% acetonitrile with equal amounts of NaOH. These substrate solutions were incubated in a reaction mixture consisting of pooled HIM (final concentration, 0.02-0.4 mg/ml) in the presence of Tris-HCl buffer (50 mM, pH 7.4), magnesium chloride (8 mM), and alamethicin at a final concentration of 50 g/mg microsomal protein. After preincubation at 37°C, UDP-GlcUA was added to initiate the enzyme reaction (final concentration, 2 mM). Each substrate solution was added to the reaction mixture until a final substrate concentration of 0.1 M (the acetonitrile concentration in the reaction mixture was 0.1%) except for quercetin, which had a final concentration of 1.0 M. The reaction was terminated at predetermined time points by mixing the reaction mixture with a 2-fold volume of chilled acetonitrile, followed by centrifugation at 15,000g for 5 min at 4°C. An aliquot of the supernatant was diluted twice with 0.1% formic acid and was injected into a liquid chromatography-tandem mass spectrometry (LC-MS/MS) apparatus to measure the concentration of unchanged compound. Intrinsic clearance values were calculated on the basis of the rate of substrate disappearance within the reaction mixture.
Cytochrome P450 Metabolism. Each substrate standard solution was prepared as described above for in vitro glucuronidation. These substrate solutions were incubated in a reaction mixture consisting of HIM (final concentration, 0.4 mg/ml) in the presence of potassium phosphate buffer (100 mM, pH 7.4) and EDTA (0.1 mM). Each substrate solution was added to the reaction mixture until a final substrate concentration of 0.1 M (the acetonitrile concentration in the reaction mixture was 0.1%) except for quercetin, which had a final concentration of 1.0 M. After preincubation at 37°C, NADPH was added to initiate the enzyme reaction. The reaction was terminated at 0, 30, 60, and 120 min by mixing the reaction mixture with a 2-fold volume of chilled acetonitrile, followed by centrifugation at 15,000g for 5 min at 4°C. An aliquot of the supernatant was diluted twice with 0.1% formic acid and was injected into an LC-MS/MS apparatus to measure the concentration of unchanged compound. Intrinsic clearance values were calculated on the basis of the rate of substrate disappearance within the reaction mixture.
Free Fraction in the Microsomal Mixture. The free fraction in the reaction mixture for all substrates except quercetin was determined at protein concentrations of 0.02, 0.2, and 0.4 mg/ml using a disposable 96-well rapid equilibrium dialysis (RED) plate (Thermo Fisher Scientific, Waltham, MA). The dialysis membrane had an 8-kDa molecular mass cutoff. Substrates were added to the acceptor side of the RED plate with the above reaction mixture minus UDP-GlcUA. Tris-HCl (50 mM), MgCl 2 (8 mM), and alamethicin (10 g/ml) were added to the acceptor side of the RED plate. The RED plate was sealed, and dialysis was performed for 6 h at 37°C. After incubation, 30 l of the acceptor side and 30 l of the donor side were removed by siphoning, and the concentrations of the unchanged compounds were determined by LC-MS/ MS. The unbound fraction of the microsomal mixture (f u, mic ) was calculated by eq. 2: f u,mic ϭ ͑unchanged compound concentration in acceptor side͒ /͑unchanged compound concentration in donor side͒ (2) When correcting for the unbound fraction within the microsomal mixture, CLu int, UGT was defined as eq. 3:
However, quercetin was extensively adsorbed to the dialysis membrane, preventing the determination of its f u, mic . Therefore, this value was cited from a previous study (Cubitt et al., 2009) . Human Recombinant UGT Reaction Screening. Human recombinant UGT reaction screening was performed with 12 commercially available human recombinant UGT Supersomes (hrUGTs). Each standard solution was incubated in a reaction mixture consisting of hrUGTs (final concentration, 0.2 mg/ml) and UDP-GlcUA (final concentration, 2 mM) in the presence of Tris-HCl buffer (50 mM, pH 7.4), magnesium chloride (8 mM), and alamethicin at a final concentration of 50 g/mg microsomal protein. Each substrate solution was added to give a final substrate concentration of 0.1 M (the acetonitrile concentration in the reaction mixture was 0.1%) except for quercetin, which had a final concentration of 1.0 M. After preincubation at 37°C, UDP-GlcUA was added to initiate the enzyme reaction. The reaction was terminated at 30 min by mixing it with a 2-fold volume of chilled acetonitrile, followed by centrifugation at 15,000g for 5 min at 4°C. An aliquot of the supernatant was diluted twice with 0.1% formic acid and was injected into an LC-MS/MS apparatus to measure the concentration of unchanged compound.
LC-MS/MS Analysis. The LC-MS/MS system consisted of API3200 (Applied Biosystems, Foster City, CA) and LC-20 AD (Shimadzu, Kyoto, Japan) series high-performance liquid chromatography systems fitted with LC-20AD pumps, an SCL-10AVP system controller, an SCL-20AC auto-sampler, and a CTO-20AC column oven (Shimadzu). Analytical conditions are described in Table 1 . A flow rate of 0.5 ml/min was used. Ion chromatograms were integrated and quantified using Analyst Software 1.4.1 (Applied Biosystems).
Estimation of Human F a F g from In Vivo Pharmacokinetics Data. Human F a F g was estimated using eqs. 4 through 6:
where CL h is hepatic clearance, CL tot is plasma-based total clearance, CL r is renal clearance, Q h is hepatic blood flow, and F is bioavailability. Because F a F g depends on Q h , three different reference values (17.1, 20.7, and 25.5 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 ) were used (Davies and Morris, 1993; Kadono et al., 2010) . Pharmacokinetic parameters were derived from the literature. R b is blood/ plasma ratio, which was also obtained from the literature or from in-house data or was assumed to be unity (neutral or basic compound) or 0.55 (acidic compound) if no value was available. For quercetin, because F is not available, this was calculated as in eq. 7: (7) where CL oral is oral clearance.
Permeability Study Using Artificial Membranes. Drug permeability experiments in parallel artificial membrane permeability assays (PAMPAs) were conducted using PAMPA Evolution from Pion, Inc. (Woburn, MA). PAMPA consisted of a 96-well microtiter plate (Pion, Inc.) and a 96-well filter plate (polyvinylidene difluoride; Millipore Corporation, Billerica, MA), so that each composite was well divided into two chambers, with a donor at the bottom and an acceptor at the top, separated by a 125-m-thick microfilter disc (0.45-m pores) coated with a 20% (w/v) dodecane solution of a lecithin mixture (Pion, Inc.). Drugs (10 mM) in dimethyl sulfoxide were prepared in a different 96-well filter plate (polyvinylidene fluoride; Corning Life Science, Lowell, MA) and were added to the donor compartments. The donor solution was adjusted to pH 6.5 (NaOH-treated universal buffer; Pion, Inc.). The plates were sandwiched together and incubated at 25°C for 2 h in a humidity-saturated atmosphere. After incubation, the sandwiched plates were separated, and both the donor and the acceptor compartments were assayed for the amount of material present by comparing their UV spectrums (270 -400 nm) with reference standards. Mass balance was used to determine the amount of material remaining in the membrane barrier. The apparent permeability coefficient (P app ) was calculated using PAMPA Evolution software (Pion, Inc.) (eq. 8):
where V is the volume of the acceptor chamber, A is the surface area of the cell monolayer, C 0 is the initial substrate concentration, and dC/dt is the change of concentration over time.
Simplified Intestinal Availability Model. F a F g was calculated using a theoretical model that combines the permeability and metabolism of epithelial cells as follows (eq. 9):
where PS inf is the apparent influx clearance from the lumen to the epithelial cells, PS eff is the efflux clearance from the cells to the lumen, CL ab is the absorption clearance from the cells to the blood, CL m is the metabolic clearance of the cells, and Q is the luminal flow rate. Kadono et al. (2010) simplified eq. 9 for highly permeable compounds assuming PS inf Ͼ Ͼ Q, PS inf Ͼ Ͼ PS eff and CL ab ϭ constant, to give the following (eq. 10):
where ␣ is the inverse of CL ab and is constant. Because it is difficult to estimate ␣ experimentally, in this study ␣ int, UGT was empirically determined by fitting human F a F g and CLu int, UGT in eq. 10 by replacing CL m with CLu int, UGT . Data Analysis. GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA) was used to fit data for CLu int, UGT and F a F g in eq. 10 using the nonlinear least-squares method.
Results
Calculation of Human F a F g from In Vivo Human Pharmacokinetic Parameters. Drugs with polar groups show a wide range of structural and physicochemical properties (Supplemental Data 1). More importantly for this study, in humans they all have glucuronide as a metabolite (Table 2) . Their pharmacokinetic parameters, including human F a F g , are summarized in Table 3 . Because F a F g values were sensitive to hepatic blood flow, three different human hepatic blood flows were used to determine human F a F g values, although this had a minimal effect on their rank order.
In Vitro Intrinsic Clearance. In vitro intrinsic clearance values are summarized in Table 4 . In vitro intrinsic clearance by human intes-
No apparent unchanged drug decrease was detected in human intestinal cytochrome P450 (P450) metabolism for all drugs except raloxifene and bazedoxifene. For these two drugs the in vitro intrinsic clearance by human intestinal P450s (CL int, P450 ) were 8.9 and 4.7 l ⅐ min Ϫ1 ⅐ mg Ϫ1 , respectively. For all substrates, CL int, UGT was much higher than CL int, P450 .
Permeability. The permeability of each substrate was examined using an artificial membrane. P app values are summarized in Table 5 . A high F a can be expected when the P app value is greater than 1.0 ϫ 10 Ϫ6 cm/s (Kadono et al., 2010) , which was seen in all 11 substrates except for quercetin and gemfibrozil.
Relationship between CLu int, UGT and F a F g . Figure 1 shows an inverse relationship between CLu int, UGT and F a F g for all three hepatic blood flows. To investigate the validity of the model, goodness-of-fit values of the SIA model and linear relationship were compared. The r 2 of the SIA model (0.92) was found to be higher than that of the linear model (0.58), indicating that the SIA model is more suitable. Human ␣ int, UGT for each hepatic blood flow was determined by the SIA model and is shown in Table 6 .
Identification of UGT Substrates Contributing to Glucuronidation. Twelve commercially available recombinant human UGTs expressed in insect cells were used to identify those UGT isoforms that contribute to glucuronidation (Fig. 2) . Certain isoforms resulted in significantly lower remaining ratios for specific drugs. For example, the remaining ratio for quercetin, which had the lowest F a F g value of all substrates examined, was insignificant for the isoforms UGT1A3 and UGT1A1. For raloxifene and bazedoxifene, which also had relatively low F a F g values, the remaining ratios for UGT1A8 and UGT1A10 were much lower than those for other isoforms. Tolfenamic acid, whose UGT isoforms have not been reported, was significantly metabolized by UGT1A1, UGT1A7, UGT1A9, UGT2B7, and UGT2B15, although its remaining ratio was significantly lower in response to UGT1A9 and UGT2B7.
Comparison of Empirical Scaling Factors. Differences between intestinal P450s and UGTs in humans or differences between rat and human ␣ int, UGT in the SIA model fitting curves were compared. The empirical scaling factor human ␣ met, P450 ϭ 0.64 was determined by the relationship between CL met, P450 and human F a F g at a hepatic blood flow of 20.7 ml ⅐ min Ϫ1 ⅐ kg
Ϫ1
, which is cited from a previous study (Kadono et al., 2010) . CL met, P450 is CL int, P450 corrected by the CL int, P450 of midazolam to normalize the lot difference of intestinal microsomes, indicating that ␣ met, P450 is a constant value among pooled HIM. The CL int, P450 of midazolam was determined by intestinal microsomes (CL int, P450 ϭ 123 l ⅐ min Ϫ1 ⅐ mg Ϫ1 ) in this study. 
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Therefore, the empirical scaling factor human ␣ int, P450 was calculated by dividing ␣ met, P450 by CL int, P450 of midazolam, resulting in ␣ int, P450 ϭ 5.2 ϫ 10 Ϫ3 at a hepatic blood flow of 20.7 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 . The fitting curves for human ␣ int, UGT and human ␣ int, P450 were almost identical (Fig. 3A) , indicating that the SIA model could indeed be applicable with UGT and P450 substrates using the same ␣ value. On the other hand, rats showed different results. The empirical scaling factor rat ␣ int, UGT ϭ 0.0021 was obtained from the relationship between rat CL int, UGT and rat F a F g described by Furukawa et al. (2012) . As seen in Fig. 3B , rat ␣ int, UGT was less than the human ␣ int, UGT , resulting in distinct fitting curves (Fig. 3 B) .
Discussion
Increasing awareness of the importance of intestinal glucuronidation has led to the need to predict this pathway's first-pass effect on drugs during the discovery stage. However, a reliable method for quantitatively predicting this effect is still lacking. The aim of this study was to consider a method for predicting the effect of intestinal glucuronidation on human intestinal availability.
The SIA model showed that CLu int, UGT and F a F g have an inverse relationship (Fig. 1) . This indicates that for highly permeable UGT substrates as well as CYP3A4 substrates, F a F g could be predicted by combining in vitro data and the SIA model. However, because of limitations in the SIA model, it is necessary that the substrates tested have high permeability. Except for quercetin and gemfibrozil, all substrates tested had P app values Ͼ 1.0 ϫ 10 Ϫ6 cm/s, indicating high absorption in human intestine (Kadono et al., 2010) . Consequently, human F a values are expected to be high. Despite its low P app value, quercetin too is expected to have a high human F a (Walgren et al., 1998) , because it has been reported that 65 to 81% of quercetin is TABLE 4 ) and reported bioavailability of 2% (Thummel et al., 2005) . c Calculated from oral clearance data (86.7 ml ⅐ min Ϫ1 ⅐ kg
In vitro intrinsic clearance by UGTs in HIM (CL int, UGT ), unbound CL int, UGT (CLu int, UGT ); in vitro intrinsic clearance by P450s in HIM (CL int, CYP ), unbound CL int, P450 (CLu int, P450 )
Drug UGT P450 f u, mic CL int, UGT CLu int, UGT f u, mic CL int, P450 CLu int, P450 l ⅐ min Ϫ1 ⅐ mg Ϫ1 l ⅐ min Ϫ1 ⅐ mg Ϫ1 mg/ml l ⅐ min Ϫ1 ⅐ mg Ϫ1 l ⅐ min Ϫ1 ⅐ mg
Ϫ1
) and reported bioavailability of 6.2% (Patat et al., 2003; Chandrasekaran et al., 2009 ). d Calculated from oral clearance data (0.82 ml ⅐ min Ϫ1 ⅐ kg
) and reported bioavailability of 80%. Etodolac (Lodine) U.S. Food and Drug Administration drug approval package (http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018922s022,020584s009lbl.pdf).
e Calculated F a F g was Ͻ 0, because CL tot /R b /Q h was Ͼ 1. Therefore, CL tot /R b was assumed to 90% of Q h . f When calculated F a F g was Ͼ 1, it was treated as 1.0. g Assumed to be 0.55 because indomethacin and etodolac are acidic drugs (Cubitt et al., 2011) .
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absorbed after oral administration in humans (Graefe et al., 2001) . Gemfibrozil is also expected to have a high F a value, because its bioavailability is approximately 100% (Thummel et al., 2005) . The inverse relationship is strengthened by the fact that all substrates tested are expected to be metabolized mainly by UGTs in the human intestine, because all but tolcapone are metabolized by P450s and UGTs (Table 2) . Although an oxidized metabolite was detected in human plasma after the oral administration of diclofenac, gemfibrozil, etodolac, and indomethacin, there was no decrease in the unchanged compound in HIM involving NADPH, indicating that intestinal P450 metabolism does not contribute to the intestinal metabolism. Only raloxifene and bazedoxifene had their CL int, P450 values determined, with both being significantly less than their respective CL int, UGT values, indicating that glucuronidation contributes to human intestinal metabolism. Although one main metabolite in humans after the oral administration of tolcapone was glucuronide, a methylated metabolite was also detected (Jorga et al., 1999) . This methylation is mediated through catechol-O-methyltransferase enzyme (COMT). However, because COMT activity is low (Ellingson et al., 1999) , and because the main metabolite was glucuronide, it is unlikely that intestinal COMT affects the F a F g of tolcapone. These results are consistent with the inverse relationship between CLu int, UGT and F a F g .
Given that oral area under the concentration-time curve (AUC) values of our selected drugs increase in almost direct proportion to oral dose (Supplemental Data 2), we conducted in vitro metabolism experiments at a relatively low concentration of 0.1 M, which is believed to be lower than general K m values of UGTs (Williams et al., 2004) . However, the predicted concentrations in human intestine (Supplemental Data 3) were much higher than 0.1 M, indicating that intestinal glucuronidation should be saturated, which contradicts the linearity of oral AUC increases. For example, a previous study found that K m values of bazedoxifene for intestinal microsomes-5.1 (bazedoxifene-4Ј-glucuronide) and 5.1 M (bazedoxifene-6Ј-glucuronide) (Shen et al., 2010) -were lower than the predicted intestinal concentration (25-170 M) at oral doses ranging from 3 to 20 mg (Supplemental Data 3); however, oral AUC values were reported to increase in proportion to oral doses from 5 to 120 mg (Supplemental Data 2). This contradiction may be explained by autoactivation and gut volume. Autoactivation has been reported for UGT substrates (Wong et al., 2007) , indicating that intestinal glucuronidation may not be saturated at concentrations close to K m values. The predicted intestinal concentration is traditionally calculated by dividing molar dose by 250 ml, the estimated volume of a glass of water. However, given that 250 ml has been reported to be smaller than the calculated intestinal fluid volume, intestinal drug-drug interaction predictions may be overestimated when 250 ml is used (Tachibana et al., 2009) . Therefore, further investigation will be required to clarify the kinetics of UGTs and the concentration in human intestine.
To clarify the UGT isoforms that contribute to the glucuronidation of each substrate, UGT isoform phenotyping was conducted using hrUGTs. Depending on the substrate, specific UGT isoforms significantly decreased the remaining ratio. For example, for raloxifene, the glucuronidation rates of UGT1A8, UGT1A9, and UGT1A10 are reported to be higher than those of other isoforms (Kemp et al., 2002) , which is consistent with our remaining ratio results. Similar consistencies were found with bazedoxifene for UGT1A1, UGT1A8, and UGT1A10 (Shen et al., 2010) , diclofenac and gemfibrozil for , and 25.5 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 (C). Solid lines were obtained by fitting with the nonlinear least-squares method. When an observed F a F g was more than 1, it was treated as 1.0. 1, quercetin; 2, raloxifene; 3, bazedoxifene; 4, diclofenac; 5, tolfenamic acid; 6, tolcapone; 7, entacapone; 8, telmisartan; 9, gemfibrozil; 10, etodolac; and 11, indomethacin. UGT2B7, and tolcapone, etodolac, and indomethacin for UGT1A9. Overall, these results indicate that the substrates were metabolized by various UGT isoforms, and that the SIA model was applicable independent of the isoform. The empirical scaling factor, ␣, which was obtained by fitting the relationship between human F a F g and intestinal intrinsic clearance, may be a hybrid of the human mucosal blood flow and a scale-up number of the ratio of UGT activity per intestinal microsome to UGT activity per body weight. The scale-up number describes glucuronidation activity per microsomal activity to glucuronidation activity per body weight and is needed to meet the unity of Q ent (ml ⅐ min Ϫ1 ⅐ kg Ϫ1 ). This is for several reasons. First, the Q gut model (Yang et al., 2007) predicts human F g from in vitro metabolic clearance and membrane permeability as follows (eqs. 11 and 12):
where Q ent is mucosal blood flow, f ugut is the fraction of unbound drug in enterocytes, and CL perm is permeability clearance, which is defined as the product of intestinal surface area and apparent or effective permeability. Yang et al. (2007) assumed f ugut ϭ 1 when applying the Q gut model. Furthermore, for highly permeable substrates, it can be assumed that CL perm Ͼ Ͼ Q ent , leading to the following (eq. 13):
By combining eqs. 9 and 13, one can show the empirical scaling factor equals the reciprocal of enterocytic blood flow corrected by the scale-up factor (that is, ␣ ϭ scale-up number/Q ent ). Second, human ␣ int, UGT values resembled human ␣ int, P450 values independently of the metabolic enzyme (Fig. 3A) . This result indicates that ␣ represents a physiological parameter such as blood flow. Third, the rank order that human ␣ int, UGT is greater than rat ␣ int, UGT is consistent with the rank order of human scale-up number/Q ent being higher than rat scale-up number/Q ent . For example, the values of mucosal blood flow are 4.6 in humans (Soars et al., 2002 ) and 14.4 ml ⅐ min Ϫ1 ⅐ kg Ϫ1 in rats, the latter being obtained by correcting rat Q ent with a rat body weight of 0.25 kg (Davies and Morris, 1993; Yang et al., 2007) . The scale-up number has been reported to be 90 in humans (Soars et al., 2002) and 34 mg/kg b.wt. in rats (Yoon et al., 2011) . Therefore, the scale-up number/Q ent in humans is 0.020 and in rats is 0.0024 min ⅐ kg/l. The rank order of ␣ int, UGT between rats and humans is consistent with that of the scale-up number/Q ent , indicating that the empirical scaling factor ␣ is in fact equivalent to the scale-up number/Q ent value. However, to validate this hypothesis, far more intestinal microsomes need to be investigated.
In summary, for highly permeable UGT substrates, CL int, UGT and F a F g showed an inverse relationship, indicating F a F g can be predicted by combining in vitro glucuronidation measurements and the SIA model. These insights indicate that in vitro glucuronidation studies and the SIA model may be able to predict the impact of intestinal glucuronidation on the first-pass effect in humans. 
